



This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Lidocaine Hydrochloride 5% and Phenylephrine Hydrochloride 0.5% topical solution

By registered health care professionals for

Analgesia for Naso–Pharynx procedures

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 43

1. Change history

Version number	Change details	Date
1	Original PGD ratified	July 2021

2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#)

3. PGD development

Refer to the [NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

5. PGD adoption by the provider

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job title and organisation	Signature	Date	Applicable or not applicable to area

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	Requirements of registered Healthcare professionals working under the PGD
Qualifications and professional registration	<ul style="list-style-type: none"> Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises
Initial training	<ul style="list-style-type: none"> Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD Local training in the use of PGD's
Competency assessment	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGD's
Ongoing training and competency	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

7. Clinical Conditions

Clinical condition or situation to which this PGD applies	Analgesia for Naso –Pharynx procedures
Inclusion criteria	Patients 12 years and older
Exclusion criteria	<ul style="list-style-type: none"> • Patient under 12 years • Hypersensitivity to Lidocaine Hydrochloride, local anaesthetics of the amide type, Phenylephrine Hydrochloride • Lidocaine and phenylephrine topical solution should not be administered to those who are pregnant or breast-feeding. • Hypovolaemia • Hypertension • acute ischaemic heart disease • Complete heart block. • Thyrotoxicosis • Glaucoma • Urinary retention. • Patients receiving other sympathomimetic drugs. • Lidocaine and phenylephrine topical solution should not be given to patients taking monoamine oxidase inhibitors or within 2 weeks of their use.
Cautions (including any relevant action to be taken)	<p>The lidocaine and phenylephrine topical solution may interfere with swallowing, and numbness of the tongue or buccal mucosa may increase the danger of biting trauma.</p> <ul style="list-style-type: none"> • Lidocaine and phenylephrine topical solution should be administered with caution to patients taking β-adrenergic blocking agents (see section below headed 'Interactions with other Medicaments and other forms of Interaction',) and those with cardiovascular disease, diabetes mellitus, hypertension or hyperthyroidism, hypoxia, hypercapnia and porphyria. • Lidocaine and phenylephrine topical solution should be used with caution in patients with traumatised mucosa and/or sepsis in the region of the proposed application. • Lidocaine and phenylephrine topical solution should also be used with caution in patients with epilepsy, impaired cardiac conduction, bradycardia, impaired hepatic function and in severe shock. • The clinician or pharmacist should check that sympathomimetic containing preparations are not simultaneously administered by several routes i.e. orally and topically (nasal, aural and eye preparations) • Sympathomimetic-containing products should be used with great care in patients suffering from angina
Arrangements for referral for medical advice	Patient should be referred to a more experienced clinical practitioner for further assessment

Action to be taken if patient excluded	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient declines treatment	<ul style="list-style-type: none"> • A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment • This information must be documented in the patients' health records • Any patient who declines care must have demonstrated capacity to do so • Where appropriate care should be escalated

8. Details of the medicine

Name, form and strength of medicine	Lidocaine hydrochloride 5% and phenylephrine hydrochloride 0.5% topical solution
Legal category	Pharmacy (P)
Indicate any <u>off-label use</u> (if relevant)	None
Route/method of administration	Topical application to mucous membranes in nasal and pharyngeal areas
Dose and frequency	Nasal: 4 sprays in to each nostril Pharynx: Up to 8 sprays
Quantity to be administered	As per dose
Maximum or minimum treatment period	Adults, and Children over 12 years: <ul style="list-style-type: none"> • Up to a maximum of 8 sprays in total.
Storage	Room temperature
Adverse effects	<ul style="list-style-type: none"> • Anxiety • Arrhythmias • Atrioventricular block • Cardiac arrest • Circulatory collapse • Confusion • Dizziness • Drowsiness • Euphoric mood • Headache • Hypersalivation • Hypertension • Hypotension (may lead to cardiac arrest) • Loss of consciousness • Methaemoglobinaemia • Muscle twitching • Myocardial contractility decreased • Nausea • Neurological effects • Nystagmus • Pain • Peripheral vasodilation or vasoconstriction • Psychosis • Respiratory disorders • Retention urine/difficulty in micturition • Seizure • Sensation abnormal • Temperature sensation altered • Tinnitus • Tremor • Vision blurred • Vomiting

Records to be kept	The administration of any medication given under a PGD must be recorded within the patient's medical records
---------------------------	--------------------------------------------------------------------------------------------------------------

9. Patient information

Verbal/Written information to be given to patient or carer	<ul style="list-style-type: none"> • Verbal information must be given to patients and or carers for all medication being administered under a PGD • Where medication is being supplied under a PGD, written patient information leaflet must also be supplied • A patient information leaflet is available on request
Follow-up advice to be given to patient or carer	If symptoms do not improve or worsen or you become unwell, seek medical advice immediately

10. Appendix A

References
<ol style="list-style-type: none"> 1. British National Formulary (BNF) available online: https://bnf.nice.org.uk 2. Nursing and Midwifery (2018) "The code" available online: https://www.nmc.org.uk 3. Current Health Care Professions Council standards of practice 4. General Pharmaceutical Council standards 5. The General Optical Council 6. Electronic medicines compendium available online: https://www.medicines.org.uk

11. Appendix B

Health professionals agreed to practice
<ul style="list-style-type: none"> • Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor • A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves